Advanced Oncotherapy great progress for the Harley Street installation says Nicolas Serandour, CEO

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy LON:AVO, said: “As I outlined in my update to shareholders in March, the Company remains focused on delivering the technical development of our first LIGHT machine and its ultimate installation at Harley Street, and I am very pleased with the progress we are making.

“We will continue to update the market with newsflow on the integration of the LIGHT system’s components, with developments on the CCL units, addition of the SCDTLs to the RFQ and on the Patient Positioning System anticipated in the coming weeks and months.”

Advanced Oncotherapy (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk about further notable progress in the manufacture of its first LIGHT system.

Patient Positioning System

Multiple components of the treatment room have been manufactured, inspected and tested by the Company’s partner P-Cure Ltd. (“P-Cure”), ahead of their integration to form a complete patient treatment system.

The patient positioning subsystem, which includes the patient treatment chair and robotic arm which moves the chair and patient, is complete and has been designed to leverage LIGHT’s next-generation features. As other subsystems are completed, such as imaging and treatment management software, they will be integrated to form the whole Patient Positioning System, which remains on track to be fully developed by the end of 2017.

Beam firing through RFQ

As indicated in the Investor presentation and update of 6 March 2017, the proton beam was fired through the Radio Frequency Quadrupole (“RFQ”), at its maximum expected energy, in February 2017. Subsequent work has focused on enhancing the proton source that feeds the RFQ; repeatability of beam firing, intensive usage to facilitate high patient throughput and maximising safety controls are all key elements of LIGHT.

Ionisation chamber

In addition, the Company announces it has received delivery of the LIGHT system’s ionisation chamber, from its partner Pyramid Technical Consultants Inc., to its Geneva testing facility. The ionisation chamber is a critical element of the LIGHT system’s overall safety system, monitoring beam position, spot size and dosage and is situated at the delivery end of the system after the main accelerating modules.

The novel design of the chamber is matched to the unique properties of LIGHT and performs a precise measurement of the position (in horizontal and vertical axes) of the proton beam, with respect to its desired location, and is a critical element of the LIGHT system’s Patient Treatment System. It also accurately monitors the dose (number of protons) delivered to the target. The properties of the LIGHT ionisation chamber allow these measurements to be taken, on a pulse by pulse basis, ensuring accuracy and safety throughout treatment, to a level that cannot be matched by older proton therapy technologies.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked